/var/www/vhosts/myeloma.org/httpdocs/spider_articles/pdfs/Citings-Q1+2-2010-TBS-SpecEd

Published by the IC
nternational M I
yeloma FT
oundation
INSG
pecial Edition: AS
SCO 2010
FreeliteTM / HevyliteTM Issue
The International Myeloma Foundation (IMF) presents this edition of CITINGS, our premiere publication featuring the most up-to-
date information on myeloma treatment, focused on two diagnostic tests from The Binding Site Group Ltd. trademarked procedures
commonly called the Freelite and Hevylite. These incredibly useful tools provide necessary diagnostic information for multiple myeloma,
amyloidosis, and other hematologic malignancies. This edition corresponds with articles published in the first half of 2010.
It is our hope that CITINGS will help keep you abreast of the latest developments in myeloma treatment. As always, we welcome your
feedback; you may contact the IMF at (800) 452-CURE (2873) or at our website www.myeloma.org.
Susie Novis, President, IMF
Serum Free Light Chain Assays Publications from the first 6 months of 2010
NNew Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock
Protein 90 Inhibitor, in Multiple Myeloma Cells.
Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y.
Clin Cancer Res. 2010 May 4. [Epub ahead of print.]
:
http://www.ncbi.nlm.nih.gov/pubmed/20406843
The authors evaluate the antitumor activities of KW-2478 in MM cells with various chromosomal translocations of immunoglobulin heavy chain
loci both in vitro and in vivo. Their results suggest that targeting diverse pathways by KW-2478 could be a promising strategy for the treatment
of myeloma with various cytogenetic abnormalities.
NQuestionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients.
Kröger N, Asenova S, Gerritzen A, Bacher U, Zander A.
Blood. 2010 Apr 22;115(16):3413-4; author reply 3414-5.
:
http://www.ncbi.nlm.nih.gov/pubmed/20413663
Comment on: Blood. 2009 Dec 3;114(24):4954-6.
NClinical usefulness of serum free light chain measurement in monoclonal gammopathy.
Shimazaki C, Murakami H, Sawamura M, Matsuda M, Kinoshita T, Hata H, Sugiura I, Tsushita K, Nagura E, Kosugi H, Itoh J,
Shimizu K.
Rinsho Ketsueki. 2010 Apr;51(4):245-52.
:
http://www.ncbi.nlm.nih.gov/pubmed/20467220
This study suggests that FREELITETM is useful for diagnosis, disease monitoring and assessment of response to treatment in patients with mono-
clonal gammopathies such as myeloma and AL amyloidosis.
NMonoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA, Rajkumar SV.
Curr Hematol Malig Rep. 2010 Apr;5(2):62-9.
:
http://www.ncbi.nlm.nih.gov/pubmed/20425398
The authors discuss the nature of smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, including their testing
by serum protein electrophoresis, immunofixation, and the free light chain (FLC) assay.
www.myeloma.org
(800) 452 - CURE (2873)
Funded by an unrestricted educational grant from Binding Site.

NSerum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy
and light chain deposition disease.
Honma R, Fukase S, Suzuki M, Omoto E.
Rinsho Ketsueki. 2010 Apr;51(4):270-4.
:
http://www.ncbi.nlm.nih.gov/pubmed/20467224
The authors perform serial serum free light chain (SFLC) assays in a patient with nonsecretory myeloma with with light chain cast nephropathy
and light chain deposition disease (LCDD). They find that the quantitative FLC assay is useful for the diagnosis and monitoring of nonsecretory
myeloma and LCDD in this patient.
N`Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series
using LC-monitoring.
Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, Engelhardt M.
J Cancer Res Clin Oncol. 2009 Mar;135(3):477-84. [Epub 2008 Sep 18.]
:
http://www.ncbi.nlm.nih.gov/pubmed/18802723
This report suggests that early detection of light-chain escape (LCE)-myeloma by means of serial serum free light chain measurements may prevent
unnecessary complications, allow the detection of unusual relapse manifestations in the era of intensive and biological therapy options, and possibly
also lead to improved treatment results in LCE-myeloma.
NSmoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome,
and follow-up recommendations.
Bladé J, Dimopoulos M, Rosiñol L, Rajkumar SV, Kyle RA.
J Clin Oncol. 2010 Feb 1;28(4):690-7. [Epub 2009 Dec 21.]
:
http://www.ncbi.nlm.nih.gov/pubmed/20026810
The authors provide an overview on smoldering (asymptomatic) multiple myeloma, including a discussion of abnormal free light chain ratio as a
risk factor for its progression.
NPrediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum
free light chain response definitions.
Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R.
Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):E10-3.
:
http://www.ncbi.nlm.nih.gov/pubmed/20223721
The authors seek to validate the proposed response and progression criteria using serum free light chain (SFLC) testing for patients with nonse-
cretory multiple myeloma as set forth by the International Myeloma Working Group. The authors find that SFLC reliably predicts response and
progression in myeloma. However, half of the patients had inevaluable disease by SFLC, thus limiting the utility of SFLC testing in patients with
nonmeasurable disease by electrophoretic methods.
NSharply increased serum free light-chain concentrations after treatment for multiple myeloma.
Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA.
Clin Chem. 2010 Jan;56(1):16-8.
:
http://www.ncbi.nlm.nih.gov/pubmed/20040623
No abstract available.
NAnalytical performance of the serum free light chain assay.
Briand PY, Decaux O, Caillon H, Grosbois B, Le Treut A, Guenet L.
Clin Chem Lab Med. 2010;48(1):73-9.
:
http://www.ncbi.nlm.nih.gov/pubmed/19929752
The authors seek to evaluate the analytical performance of the serum free light chain (SFLC) assay. Their data demonstrate that the results of
the SFLC assay must be interpreted jointly by the clinician and the biologist, taking into account the individual patient's clinical and biological
characteristics.
NMultiple myeloma with monoclonal free IgG3 heavy chains and free kappa light chains.
Richter AG, Harding S, Huissoon A, Drayson M, Pratt G.
Acta Haematol. 2010;123(3):158-61. [Epub 2010 Mar 10.]
:
http://www.ncbi.nlm.nih.gov/pubmed/20215741
The authors present the first description, investigation and treatment of myeloma with a plasma cell population producing truncated gamma(3)
heavy chain and kappa free light chain M-proteins, a case that illustrates a number of unique immunological and clinical features.
www.myeloma.org
(800) 452 - CURE (2873)

NAbnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association
with the presence of oligoclonal bands: implications for stringent complete remission definition.
de Larrea CF, Cibeira MT, Elena M, Arostegui JI, Rosiñol L, Rovira M, Filella X, Yagüe J, Bladé J.
Blood. 2009 Dec 3;114(24):4954-6. [Epub 2009 Oct 1.]
:
http://www.ncbi.nlm.nih.gov/pubmed/19797521
The authors study the prevalence of an abnormal serum free light chain (SFLC) ratio in 34 patients with multiple myeloma in complete response
(CR) after hematopoietic stem cell transplantation, resulting in the first report showing that the presence of oligoclonal bands in patients with
myeloma in CR frequently results in an abnormal SFLC ratio.
NUse of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant
plasma cell disorders.
Vermeersch P, Vercammen M, Holvoet A, Broeck IV, Delforge M, Bossuyt X.
Clin Chim Acta. 2009 Dec;410(1-2):54-8. [Epub 2009 Sep 22.]
:
http://www.ncbi.nlm.nih.gov/pubmed/19778527
The authors examine whether the use of test result interval-specific likelihood ratios (LR) could improve the clinical interpretation of serum FLC
kappa/lambda ratio for the diagnosis of malignant plasma cell disorders. They conclude that interpreting serum FLC kappa/lambda ratios using
LRs for different result intervals improves the clinical interpretation for the diagnosis of malignant plasma cell disorders, excluding plasmacytoma.
NComplete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition
disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and
review of literature. [Article in Czech]
Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
Vnitr Lek. 2009 Nov;55(11):1089-96.
:
http://www.ncbi.nlm.nih.gov/pubmed/20017442
The authors document the importance of plasma free light chain detection.
www.myeloma.org
(800) 452 - CURE (2873)

(800)452-CURE (2873)
www.myeloma.org